Core Laboratories N.V.
NYSE:CLBOil & Gas Equipment & Services
+$0.12 today
- Market cap
- $387.21M
- Beta
- 0.99
- P/E (TTM)
- 18.3
- EPS (TTM)
- $0.63
- Dividend yield
- 0.35%
Volume 0.52M
Average 0.49M
CLB Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Core Laboratories N.V.NYSE: CLB
Net Income · Q1 FY2026 · quarter ended Mar 2026
Net income turns negative
Q1 FY2026 net income was -$753K, compared with $69K a year earlier. Trailing-twelve-month net income was $31.49M. Over 3 fiscal years it compounded at +17.4% a year.
Context
- Net income amounted to 6.0% of revenue in FY2025, unchanged from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 2 analysts of $21.88M (-31.2%) for the fiscal year ending Dec 2026, a slowdown from the -1.1% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$753K-110.6% QoQ
- Last fiscal yearDec 2025
- $31.8M-1.1% YoY
- LTMMar 2026
- $31.49M+10.6% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -1191.3% | -61.8% | +1129.5 pp |
| 1 year | -1.1% | -31.2% | -30.1 pp |
| 3-year CAGR | +17.4% | +9.8% | -7.6 pp |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- 31.8M USD
- Year-over-year change
- -1.1%
- 4-year CAGR
- +12.0%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 31.8M | -1.1% |
| FY2024 | 2024-12-31 | 32.15M | -13.2% |
| FY2023 | 2023-12-31 | 37.03M | +88.3% |
| FY2022 | 2022-12-31 | 19.66M | -2.8% |
| FY2021 | 2021-12-31 | 20.22M | — |
Net Income vs competitors
How CLB compares with its peers on the latest reported figures
- Peers report in different currencies, so net income is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +10.6% is the 4th highest of 10, against a peer median of -43.1%.
- Net income amounts to 6.0% of revenue for CLB, versus a peer median of 7.1%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $497.64M USD | +30.5% | +441.0% | 39153.7% | |
| LTM Mar 2026 | $321.52M USD | +737.9% | — | 9.9% | |
| LTM Mar 2026 | $145.32M USD | -221.0% | -58.5% | 18.8% | |
| LTM Mar 2026 | $98.37M USD | -728.8% | +41.3% | 27.7% | |
| LTM Mar 2026 | $59.61M USD | +74.3% | -13.1% | 1.6% | |
| LTM Mar 2026 | $32.9M USD | -35.2% | — | 3.1% | |
| LTM Mar 2026 | $31.49M USD | +10.6% | +17.4% | 6.0% | |
| LTM Mar 2026 | $19.67M USD | -175.9% | -40.3% | 7.1% | |
| LTM Mar 2026 | CA$14.7M CAD | -113.4% | — | 0.8% | |
| LTM Mar 2026 | $6.99M USD | -43.1% | -54.7% | 1.5% | |
| Peer median (excluding CLB) | — | -43.1% | -26.7% | 7.1% | |
Competitors are the stored peer set for CLB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 20.22M | 19.66M | 37.03M | 32.15M | 31.8M |
| Depreciation & Amortization | 18.52M | 17.16M | 15.78M | 14.95M | 14.65M |
| Deferred Income Tax | 6.01M | 433K | (10.81M) | 674K | (4.74M) |
| Stock-Based Compensation | 19.09M | 7.76M | 13.97M | 3.76M | 7.14M |
| Change in Working Capital | (24.25M) | (25.02M) | (28.77M) | 7.88M | (5.57M) |
| Accounts Receivables | (13.52M) | (10.08M) | (2.62M) | (3.61M) | (4.95M) |
| Inventory | (4.55M) | (14.86M) | (12.98M) | 9.37M | 2.64M |
| Accounts Payables | 6.57M | 15.37M | (12.88M) | 519K | 477K |
| Other Working Capital | (12.75M) | (15.46M) | (300K) | 1.61M | (3.73M) |
| Other Non-Cash Items | (3.01M) | 4.97M | (2.41M) | (3.03M) | (6.11M) |
| Operating Cash Flow | 36.58M | 24.96M | 24.79M | 56.39M | 37.18M |
| Capital Expenditures | (13.54M) | (10.22M) | (10.58M) | (13.03M) | (14.59M) |
| Acquisitions (Net) | 873K | 240K | 0 | 0 | (1.24M) |
| Purchases of Investments | 13.54M | 0 | 0 | 0 | 0 |
| Sales of Investments | 726K | 0 | 0 | 0 | 0 |
| Other Investing Activities | (11.82M) | 6.12M | 3.93M | 6.63M | 13.6M |
| Investing Cash Flow | (10.22M) | (3.86M) | (6.65M) | (6.39M) | (2.23M) |
| Debt Repayment | (71M) | (15M) | (9M) | (38M) | (16.71M) |
| Common Stock Issued | 60M | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | (8.26M) | (3.9M) | (2.2M) | (5.31M) | (12.43M) |
| Dividends Paid | (1.83M) | (1.85M) | (1.87M) | (1.88M) | (1.87M) |
| Other Financing Activities | (1.37M) | (2.62M) | (5.38M) | (775K) | (254K) |
| Financing Cash Flow | (22.46M) | (23.38M) | (18.45M) | (45.96M) | (31.26M) |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 3.9M | (2.28M) | (308K) | 4.04M | 3.69M |
| Free Cash Flow | 23.04M | 14.74M | 14.21M | 43.36M | 22.59M |
Core Laboratories N.V.
NYSE:CLB
Intrinsic Alpha fair value
Locked
Current Price
$8.45
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.